Needham & Company analyst Ami Fadia reiterated a Buy rating and $65.00 price target on Intra-Cellular Therapies (NASDAQ: ITCI), following ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE